Dr. Lal PathLabs Limited Set to Consider Q2 FY27 Results

Dr. Lal PathLabs Limited is scheduled to consider its unaudited Q2 FY27 results for the quarter ended 30 September 2026 on 4 November, following Q1 revenue growth of 19.1% year-on-year to ₹797.70 crore. The board will also consider a second interim dividend, if any, for FY27.

What is Dr. Lal PathLabs scheduled to consider on 4 November 2026?

Dr. Lal PathLabs is scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. The meeting of the board of directors is set for Wednesday, 4 November 2026, according to the company’s regulatory intimation.

The agenda also includes considering a second interim dividend on equity shares for FY27, if any. The company has not disclosed an amount or other financial impact for a potential second dividend, as a decision remains subject to board approval. The disclosure was signed by Vinay Gujral, Company Secretary and Compliance Officer, on 27 October 2026.

The company has also announced an investor conference call at 6:00 PM IST on 4 November to discuss its Q2 and H1 FY27 financial and operating performance. The call is expected to include the Executive Chairman and chief executive officers, providing shareholders with management commentary after the results are considered.

For compliance with SEBI’s insider-trading regulations, Dr. Lal PathLabs closed its trading window from 1 October through 6 November 2026. This restriction covers trading in the company’s securities during the period surrounding the results review.

How did Dr. Lal PathLabs perform in Q1 FY27?

Dr. Lal PathLabs reported Q1 FY27 net sales turnover of ₹797.70 crore, up 19.1% from ₹669.80 crore in the year-earlier quarter and 13.52% from ₹702.70 crore in the preceding quarter. The June 2026 quarter provides the latest reported financial reference before the board’s review of the September-quarter numbers.

Operating profit rose to ₹247.50 crore in Q1 FY27 from ₹192.30 crore a year earlier and ₹186.80 crore in the March 2026 quarter. EBITDA stood at ₹279.40 crore, compared with ₹220.40 crore in June 2025, representing year-on-year growth of about 28.7% based on the reported figures.

Reported profit after tax was ₹170.50 crore, against ₹134.00 crore in June 2025 and ₹132.20 crore in March 2026. The company’s reported Q1 profit growth was about 27% year-on-year. Earnings before tax increased to ₹228.70 crore from ₹181.10 crore a year earlier.

Which recent corporate developments form the backdrop to Q2 FY27?

Dr. Lal PathLabs enters the Q2 FY27 announcement after reporting acquisitions involving SN Genelab and Centrapath Labs during late September and early October 2026. The company approved and closed the acquisition of a 70% stake in SN Genelab for up to ₹168.00 crore, along with an earn-out of up to ₹31.50 crore.

The company also completed the acquisition of the remaining 30% equity stake in Centrapath Labs. The supplied disclosures do not provide a quantified effect of these transactions on Q2 revenue, margins, profit, or cash flows. Their relevance to the results discussion is therefore limited to the announced change in the company’s ownership and operating portfolio.

Earlier, at its board meeting on 24 July 2026, Dr. Lal PathLabs approved unaudited standalone and consolidated results for the quarter ended 30 June 2026. At the same meeting, it declared an interim dividend of ₹5 per equity share, equal to 50% of the ₹10 face value, for FY27.

The Q2 board meeting follows an earlier intimation dated 25 September 2026. The November agenda expands the discussion from the quarterly financial statement to the half-year ended September 2026, as well as a possible second interim dividend.

What will investors assess in the Q2 FY27 announcement?

Investors will assess whether the revenue and profit growth reported in Q1 FY27 continued through the September quarter. The available Q1 figures show sales moving from ₹669.80 crore in June 2025 to ₹797.70 crore in June 2026, while reported PAT rose from ₹134.00 crore to ₹170.50 crore over the same period.

Profitability will be another measurable point of focus because operating profit grew faster than sales in Q1 FY27. Operating profit was ₹247.50 crore in the June 2026 quarter, compared with ₹192.30 crore a year earlier. The Q2 financial statement and the scheduled conference call will provide the company’s reported figures and management commentary for the subsequent quarter.

Shareholders will also watch for the board’s decision on the proposed second interim dividend. A first interim dividend of ₹5 per equity share was declared in July, but the company has not stated whether another payout will be approved or what its amount could be.

The announced acquisitions are another operational item for investors to track. Any discussion of their integration, contribution, or costs would need to come from the Q2 results release or management commentary, since the pre-results disclosures do not quantify their financial contribution.

Conclusion

Dr. Lal PathLabs will place its Q2 and H1 FY27 financial performance before the board on 4 November 2026, after a Q1 in which revenue reached ₹797.70 crore and reported PAT was ₹170.50 crore. The meeting also covers a possible second interim dividend, while the evening conference call is scheduled to provide additional context on results and operations.

The next confirmed event is the board meeting and investor call on 4 November 2026 at 6:00 PM IST. Investors will watch for the reported September-quarter sales, profit and margin figures, the board’s dividend decision, and any company commentary on the SN Genelab and Centrapath Labs transactions.